manilatimes3d
C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to ...
EU medicines agency quits X, moves to Bluesky
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have ...
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
EURACTIV5d
Smaller EU states risk being left behind in critical medicines market, says Belgian MEP Sommen
Belgian MEP Liesbet Sommen spoke with Euractiv about critical medicines shortages, EU Pharma Package progress, and SANT's evolving role.
PharmiWeb1d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
CSL, Arcturus Therapeutics announce European Commission approval for Kostaive
CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...
The Straits Times25d
EU medicines agency quits X, moves to Bluesky
AMSTERDAM – The European Medicines Agency (EMA) said on Jan 27 that it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media ...
Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...